] . Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665. 
(237.99 KB)
(237.99 KB). Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123. (501.41 KB)
(501.41 KB). External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711. (149.83 KB)
(149.83 KB). Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237. (986.49 KB)
(986.49 KB). Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC Med. 2017;15(1):68. (932.74 KB)
(932.74 KB). Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61. (463.16 KB)
(463.16 KB). Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62. (317.15 KB)
(317.15 KB). Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62. (178.71 KB)
(178.71 KB). Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714. (383.37 KB)
(383.37 KB). The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8. (370.8 KB)
(370.8 KB). Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809. (269.78 KB)
(269.78 KB)